Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for immune-inflammatory diseases. The company's strategic focus lies in addressing significant unmet medical needs within this therapeutic area, leveraging its scientific expertise to advance a diverse pipeline of drug candidates. Aclaris operates with a dual approach, encompassing both its internal drug development efforts and a contract research segment that offers laboratory services. Its pipeline includes several promising molecules targeting various aspects of the immune response. Notably, the company is progressing ATI-1777, a soft JAK 1/3 inhibitor, through Phase 2b trials for atopic dermatitis and other dermatologic conditions. Additionally, Bosakitug (ATI-045), an anti-TSLP monoclonal antibody, is in Phase 2a trials for moderate to severe atopic dermatitis, asthma, and other respiratory and inflammatory conditions. Aclaris is also investigating ATI-2138, an oral inhibitor of ITK and JAK3, for T cell-mediated autoimmune diseases, and Zunsemetinib (ATI-450), a kinase inhibitor, in early-stage trials for certain cancers. The company's commitment to innovation extends to preclinical candidates like ATI-052, a bispecific antibody designed to treat a range of atopic, immunologic, and respiratory diseases. Founded in 2012 and headquartered in Wayne, Pennsylvania, Aclaris Therapeutics is positioned to make meaningful contributions to the treatment landscape for patients suffering from debilitating immune-inflammatory conditions.